Oral delivery of taxanes

Investigational New Drugs

Volumn 19, Issue 2, 2001, Pages 155-162

  Malingré, Mirte M ^a,b   Beijnen, Jos H ^a,b,c   Schellens, Jan H M ^a,c  

^a NETHERLANDS CANCER INSTITUTE   (Netherlands)

^b SLOTERVAART HOSPITAL   (Netherlands)

^c UTRECHT UNIVERSITY   (Netherlands)

Author keywords

Bioavailability; Cytochrome P450; Docetaxel; Oral administration; P glycoprotein; Paclitaxel

Indexed keywords

CYCLOSPORIN A; CYTOTOXIC AGENT; DOCETAXEL; GLYCOPROTEIN P; PACLITAXEL; TAXANE DERIVATIVE; VALSPODAR;

ARTICLE; CANCER INHIBITION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG COST; DRUG DELIVERY SYSTEM; DRUG SAFETY; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; MULTIDRUG RESISTANCE; PHASE 2 CLINICAL TRIAL; PHENOTYPE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

ADMINISTRATION, ORAL; ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BIOLOGICAL AVAILABILITY; CYCLOSPORINE; CYCLOSPORINS; HUMANS; MICE; MICE, KNOCKOUT; NEOPLASMS; P-GLYCOPROTEIN; PACLITAXEL; TAXOIDS;

EID: 0035012398     PISSN: 01676997     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1010635000879     Document Type: Article

References (54)

1. Oral chemotherapy: Rationale and future directions
2. Clinical pharmacology of anticancer agents in relation to formulations and administration routes
3. Patient preferences for oral versus intravenous palliative chemotherapy
4. Treatment of non-small cell lung cancer with prolonged oral etoposide
5. The oral route for the administration of cytotoxic drugs: Strategies to increase the efficiency and consistency of drug delivery
6. Paclitaxel (Taxol)
7. Taxanes: A new class of antitumor agents
8. Pharmacokinetics of paclitaxel in experimental animals. Part 1. Blood levels
9. Plasma pharmacokinetics and tissue distribution of paclitaxel in CD2F1 mice
10. Disruption of the mouse mdr 1a P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs
11. Normal viability and altered pharmacokinetics in mice lacking mdr1-type (drug-transporting) P-glycloproteins
12. Mice with disrupted P-glycoprotein genes
13. A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants
14. The biochemistry of P-glycoprotein-mediated multidrug resistance
15. Biochemistry of multidrug resistance mediated by the multidrug transporter
16. Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues
17. Expression of a multidrug-resistance gene in human tumors and tissues
18. The pharmacological role of P-glycoprotein in the blood-brain barrier
19. The pharmacological role of P-glycoprotein in the intestinal epithelium
20. Human (MDR1) and mouse (mdr1, mdr3) P-glycoproteins can be distinguished by their respective drug resistance profiles and sensitivity to modulators
21. Classical and novel forms of multidrug resistance and the physiological functions of P-glycoproteins in mammals
22. What have we learnt thus far from mice with disrupted P-glycoprotein genes?
23. Limited oral bioavailability and active epithelial excretion of paclitaxel (Taxol) caused by P-glycoprotein in the intestine
24. Enhanced oral bioavailability of paclitaxel in mice treated with the P-glycoprotein blocker SDZ PSC 833
25. Nonlinear pharmacokinetics of paclitaxel in mice results from the pharmaceutical vehicle Cremophor EL
26. Human cytochrome P450 3A4: Enzymatic properties of a purified recombinant fusion protein containing NADPH-P450 reductase
27. Metabolism of Taxol by human hepatic microsomes and liver slices: Participation of cytochrome P450 3A4 and an unknown P450 enzyme
28. Enhanced oral absorption and decreased elimination of paclitaxel in mice with cyclosporin A
29. Co-administration of cyclosporin A enables oral therapy with paclitaxel
30. Coadministration of oral cyclosporin A enables oral therapy with paclitaxel
31. Nonlinear pharmacokinetics and metabolism of paclitaxel and its pharmacokinetic/pharmacodynamic relationship in humans
32. Pharmacokinetics of paclitaxel and carboplatin in a dose escalating and sequencing study in patients with non-small cell lung cancer
33. Full blockade of intestinal P-glycoprotein and extensive inhibition of blood-brain barrier P-glycoprotein by oral treatment of mice with PSC833
34. Increased accumulation of doxorubicin and doxorubicinol in cardiac tissue of mice lacking mdr1a P-glycoprotein
35. Cyclosporin A (CsA) strongly enhances oral bioavailability of paclitaxel (pac) in cancer patients
36. Phase I and pharmacokinetic study of oral paclitaxel
37. Clinical pharmacology of oral paclitaxel in a dose-escalating study
38. Bioavailability of low-dose oral etoposide
39. A phase I and pharmacology study of an oral platinum complex, JM216: Dose-dependent pharmacokinetics with single-dose administration
40. Hypersensitivity reactions to the taxanes paclitaxel and docetaxel
41. Hypersensitivity reactions from Taxol
42. Suspected anaphylactic reaction to Cremophor EL diluent
43. Oral absorption of Paxene (paclitaxel) following cyclosporin A in cancer patients
44. Tissue distribution, metabolism and excretion of paclitaxel in mice
45. Cremophor EL-mediated alteration of paclitaxel distribution in human blood: Clinical pharmacokinetic implications
46. Cremophor EL causes (pseudo)-nonlinear pharmacokinetics of paclitaxel in patients
47. Metabolism and excretion of paclitaxel after oral administration in combination with cyclosporin A and after intravenous administration
48. A phase I and pharmacokinetic study of bi-daily dosing of oral paclitaxel in combination with cyclosporin A
49. Pharmacokinetics of paclitaxel and metabolites in a randomized comparative study in platinum-pretreated ovarian cancer patients
50. Cyclosporin A strongly enhances the oral bioavailability of docetaxel in cancer patients
51. Co-administration of cyclosporin A strongly enhances the oral bioavailability of docetaxel
52. Phase I trial of docetaxel administered by weekly infusion in patients with advanced refractory cancer
53. Activity of weekly Taxotere (TXT) in patients with metastatic breast cancer
54. Weekly docetaxel in patients with advanced malignancies. Toxicity profile and activity results